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The origin and function of DN T cells are somewhat unclear and discussed controversially. While DN T cells re-
semble a rare and heterogeneous T cell subpopulation in healthy individuals, numbers of TCRαβ+ DN T cells
are expanded in several inﬂammatory conditions, where they also exhibit distinct effector phenotypes and inﬁl-
trate inﬂamed tissues. Thus, DN T cells may be involved in systemic inﬂammation and tissue damage in autoim-
mune/inﬂammatory conditions, including SLE, Sjögren's syndrome, and psoriasis. Here, the current
understanding of the origin and phenotype of DN T cells, and their role in the instruction of immune responses,
autoimmunity and inﬂammation will be discussed in health and disease.
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The presence of activated self-reactive T cells is a hallmark of various
autoimmune/inﬂammatory disorders [1]. Through the instruction of in-
ﬂammatory responses and tissue damage, T cells centrally contribute to
the pathophysiology of autoimmune disease through the generation of
a sometimes (relatively) disease-speciﬁc cytokine milieu, chemo-− (double negative) T cells in autoimmunity, Autoimmun Rev (2018),
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toantibody production by B cells [1].
Themajority of human andmurine T cells express and rearrange the
α and β chains of the T cell receptor (TCR) and are therefore referred to
as TCRαβ T cells [2]. A rare subset of T cells expresses the γ and δ chains
of the TCR, and is mostly CD4− and CD8− (DN). TCRγδ+ T cells repre-
sent a separate lineage with distinct phenotype and unique properties
[3]. In both humans and mice, approximately 95% of T cells express
TCRαβ, whereas 5% of T cells express TCRγδ [4]. Though very complex
and beyond the scope of this review, generally, TCRαβ+ T cells are con-
sidered prototypical members of the adaptive immune system, while
TCRγδ+ T cells may be activated by classical triggers of the innate im-
mune system, including heat shock protein derived peptides [5].
Among TCRαβ+ T cells, CD8+ and CD4+ T cells are the most common
subsets. However, CD4−CD8−, so-called ‘double negative’ (DN) T cells
comprise an additional, usually very small subset that has been sug-
gested to contribute to the pathophysiology of several autoimmune/in-
ﬂammatory conditions [6,7].
Historically, TCRαβ+ DN T cells have been considered “abnormal”
and/or disease-causing. This assumption was based on massively
increased numbers of DN T cells in the peripheral blood and their accu-
mulation in secondary lymphoid organs in Fas-deﬁcient lpr (lympho-
proliferation) and gld (generalized lymphoproliferation) mice,
resulting in lymphadenopathy and splenomegaly [8–10]. Later on, a
phenotypically very similar disease was described in humans several
years and termed autoimmune lymphoproliferative syndrome (ALPS)
[11,12]. Indeed, in affected humans, as well as aforementioned animals,
deﬁciency of Fas (lprmice; Faslpr) or Fas ligand (gldmice; FasLgld) (FasL)
was linkedwith disease expression [13–15]. Our current understanding
of pathological DNT cell number expansion includes the hypothesis that
usually Fas-mediated apoptosis removes DN T cells from the peripheral
blood, which is impaired in ALPS patients and Fas- or FasL-deﬁcient an-
imals [16]. Pathogenic DN T cells exhibit defects in peripheral tolerance
and contribute to lymphoproliferation and systemic inﬂammation.
Thus, Fas- and FasL-deﬁcient animals serve not only as model systems
for ALPS, but also other autoimmune/inﬂammatory conditions that are
characterized by increased numbers of DN T cells, including Sjögren's
syndrome [17] and Systemic Lupus Erythematosus (SLE) [1,7].
Though associated with several inﬂammatory conditions, DN T cells
can also be found in the peripheral blood and tissues of healthy individ-
uals. In humans and rodents, DN T cells represent a relatively small sub-
population of approximately 1–3% of all CD3+ T lymphocytes in the
peripheral blood [18,19]. Double negative T cells are also present in sec-
ondary lymphoid organs of healthy individuals, but more common in
certain non-lymphoid tissues, such as murine and human kidneys
[20,21], intestinal epithelium [22], and the murine female genital tract
[23]. Thus, more recent studies focusing on the presence and function
of DN T cells in humans and rodents suggestedDNT cells as components
of the “healthy” immune system. Indeed, DN T cells contribute to phys-
iological immunological responses against intracellular bacteria [24–26]
or the Inﬂuenza A virus [27] inmice, implicating distinct functions of DN
T cells in host defense mechanisms.
Despite recent advances, our understanding of DN T cells in health
and disease remains incomplete. This is partially based on their low fre-
quencies in (particularly healthy) humans and mice. As a result, origin,
differentiation mechanisms, and function of DN T cells remain unclear
and are discussed somewhat controversially [6,28]. In the following, re-
cent developments in understanding the origin, phenotype and (patho-
)physiological role of DN T cells will be discussed in health and disease.
2. Materials and methods
A PubMed-based literature search was performed using the search
stings “Double negative T cells”, “CD4−CD8− T cells”, “T cell differentia-
tion”, “T cell generation” and their combination with “gene expression”,
“surface expression”, “pathophysiology”, “cytokine”, “epigeneticPlease cite this article as: Brandt D, Hedrich CM, TCRαβ+CD3+CD4−CD8
https://doi.org/10.1016/j.autrev.2018.02.001regulation”, “inﬂammation”, “therapy”, “treatment”, “disease”,
“Sjögren's syndrome”, “Systemic lupus erythematosus”, and “psoriasis”.
Furthermore, the authors used their personal collection of PubMed-
listed published manuscripts on the topic (that included manuscripts
that were to be found under the aforementioned search strings).
3. The origin of DN T cells
Regardless of recent scientiﬁc efforts to describe the source and
function of DN T cells, their origin and role in immune mechanisms
are only incompletely understood. Heterogeneous surface marker ex-
pression, aswell as cytokine and chemokine expression proﬁles, suggest
that variable sources and/or differentiation pathways may exist [6]. In-
deed, even the precise lineage afﬁliation of DN T cells remains some-
what unclear and may be different between species (humans vs.
mice). Still, most available data derive from murine systems [10].
3.1. Thymus-derived DN T cells
During “normal” T cell development, thymocytes undergo several
differentiation steps, which include four “double negative” stages (DN
thymocytes) in mice and three in humans [29]. After passing these DN
stages, murine thymocytes subsequently differentiate via CD8+ imma-
ture single positive stage (ISP) into CD4+CD8+ “double positive” (DP)
cells, before they ﬁnally commit to exclusive expression of either CD4
or CD8 [30] (Fig. 1). Human DN thymocytes mature via the CD4+ ISP
stage into DP cells [31].
As mentioned before, 1–3% of peripheral T cells in healthy individ-
uals are TCRαβ+ DN T cells, and their number can be increased in auto-
immune/inﬂammatory conditions [6,32,33]. One hypothesis potentially
explaining the presence of DN T cells in the peripheral blood includes
DN T cells escaping negative selection in the thymus, and their subse-
quent activation and expansion in the periphery [34–36].
As mentioned above, TCRαβ or TCRγδ lineage commitment in mice
and humans is a result of complex TCR gene rearrangement [37]. In
mice, later DN thymocyte stages (DN3) during T cell differentiation
were suggested to give rise to either TCRαβ+ DN T cells or TCRγδ+
DN T cells, depending on the strength of TCR signal [38] or sex ste-
roid-induced release [39] (Fig. 1A). Alternatively, murine DP thymo-
cytes can give rise to DN T cells that then migrate to the intestinal
epithelium to become intraepithelial resident TCRαβ+ DN T lympho-
cytes (IEL) [36,40] (Fig. 1B). Furthermore, presentation of high-afﬁnity
ligands to DP thymocytes by cortical thymic epithelial cells in vitro re-
sulted in immunoregulatory TCRαβ+ DN T cell differentiation [41].
Of note,most studies implicating the thymus as the source of periph-
eral DNT cells relied on TCR transgenicmice. However, interpretingmu-
rine models with transgenic TCR expression can be challenging and
should take into account that TCR expression in thesemodels is already
present in “early”DN thymocytes. This is in contrast to endogenous TCR
expression that is not present before late DN thymocyte stages (DN3/4)
or the DP stage [42] (Fig. 1). Indeed, engaging the transgenic TCR with
high-afﬁnity ligands may result in abnormal thymic selection processes
[43–45].
3.2. Molecular mechanisms of DN thymocyte generation
The engagement or repression of genomic regulatory elements, in-
cluding promoters and enhancer regions plays a central role during
cell fate decisions of T cells while undergoing thymic maturation and
also later differentiations steps [46,47]. During T cell differentiation,
transcription factor recruitment to regulatory elements regulates
stage- and/or lineage-speciﬁc gene expression. In addition to the ab-
sence or presence of transcription factors, their recruitment to regula-
tory elements can be regulated through chromatin accessibility. So-
called epigenetic events regulate gene expression through chromatin
re-arrangement regulating its accessibility to transcription factors and− (double negative) T cells in autoimmunity, Autoimmun Rev (2018),
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Fig. 1.Origin of DNT cells.Mature “single positive cells” (SP) in the periphery (CD4+ or CD8+ T cells) derive fromCD4+CD8+ “double positive” (DP) cells that derive from immature single
positive stages (ISP). (A) Late stage double negative (DN3) thymocytes can give rise to either TCRαβ+DNT cells or TCRγδ+DNT cells [38,39]. (B) Alternatively, DNT cellsmay derive from
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derlying DNA sequence. Epigenetic mechanisms comprise several
events, namely DNAmethylation and post-translational histonemodiﬁ-
cations [48–50].
Epigenetic mechanisms are involved in the regulation of the CD8
gene cluster during T cell development in the thymus. Four genomic el-
ements in the murine and six elements within the human CD8 gene
cluster with lineage-speciﬁc DNase sensitivity have been identiﬁed
[51,52] (Fig. 2A). Transgenic murine reporter systems identiﬁed four
pivotal enhancer elements within the Cd8 cluster (E8I–E8IV) [51–62].
Tight regulation of the resulting enhancer network orchestrates line-
age-speciﬁc CD8α (encoded by Cd8a) and CD8β (encoded by Cd8b) ex-
pression during T cell development [47]. The heterodimer CD8αβ plays
a crucial role during thymic selection, and its expressionmarks thymus-
derived CD8+ T cells [63]. Surface expression of CD8α homodimers is
characteristic for peripherally derived CD8+ T cells (e.g. gut derived)
[64].
To allow stage- and lineage-speciﬁc CD8 expression, enhancer ele-
ments E8I–E8IV undergo epigenetic remodeling during T cell develop-
ment either permitting or terminating the expression of CD8A and/or
CD8B [52]. Low degrees of DNAmethylation along the Cd8 gene cluster
in CD4+CD8+ and CD8+ T cells allow the expression of murine Cd8a
and Cd8b, whereas increased levels of DNA methylation at the Cd8a
and Cd8b genes in CD4+ and DN T cells prohibit gene expression [65].
3.3. Thymus-independent generation of DN T cells
Studies in humans and mice suggested that at least a subset of DN T
cells may be the end product of thymus-independent processes [23,66].
Several lines of evidence support the hypothesis that DN T cells can de-
rive from activated peripheral CD4+ and/or CD8+ T cells. Zhang et al.
showed that mature murine peripheral CD4+ (CD25+/Foxp3+ and
CD25−/Foxp3−) T cells can convert to MHC II-restricted DN T cells in
vitro and in vivo and exert regulatory function [67]. More recently,
Grishkan et al. demonstrated that “chronic” (by the authors deﬁned as
more than three weeks) in vitro stimulation of murine spleen-derived
CD4+ T helper cells results in the generation of DN T cells that show ef-
fector phenotypes [68] (Fig. 1C). Conversely, (short term; 5 days) in
vitro stimulation of human CD4+ T cells did not result in DN T cell gen-
eration [69].Please cite this article as: Brandt D, Hedrich CM, TCRαβ+CD3+CD4−CD8
https://doi.org/10.1016/j.autrev.2018.02.001Accumulating evidence supports the hypothesis that DN T cells can
derive from activated peripheral CD8+ cells through the down-regula-
tion of CD8 surface co-receptor expression (Fig. 1D). In both Fas-deﬁ-
cient MRL.lpr mice and human autoimmune lymphoproliferative
syndrome patients, the majority of DN T cells have been demonstrated
to derive from CD8+ T cells [70–72]. Moreover, in response to in vitro
TCR complex stimulation, a subset of CD8+ T cells derived from healthy
human subjects transformed into DN T cells through the down-regula-
tion of CD8 co-receptor expression [69,72]. These ﬁndings are in agree-
ment with studies in mice displaying accumulation of DN T cells in
response to antigen-speciﬁc in vivo stimulation of TCR transgenic
CD8+ T cells in vivo [73,74].
3.4. Molecular mechanisms of peripheral DN T cell generation
Several molecular mechanisms are involved in activation-induced
transformation of peripheral CD8+ T cells into DN T cells. The transcrip-
tion factor cAMP responsive element modulator (CREM)α recruits to
several elements within the human and the murine CD8 cluster.
Trans-repression of the CD8B promoter and an additional enhancer ele-
ment (CNS2) through CREMα results in transcriptional silencing and
down-regulation of CD8 surface expression [72] (Fig. 2B). Furthermore,
CREMα orchestrates recruitment of DNA methyltransferase (DNMT)3a
and histone methyltransferase G9a, mediating stable epigenetic silenc-
ing through DNA and histone methylation of the CD8 gene cluster [75]
(Fig. 2B). To date, however, it is not clear whether CREMα exclusively
regulates the CD8 cluster in peripheral CD8+ T cells in response to
TCR activation or whether it also participates in the regulation of chro-
matin remodeling during the priming and differentiation of T cells in
the thymus [75].
Furthermore, the transcription factor Runt-related transcription fac-
tor (RUNX)3 may also inﬂuence the epigenetic landscape of CD8+ T
cells in mice. In activated murine CD8+ T cells, maintenance of CD8
co-receptor expression is dependent on RUNX3 and the Runx/core
binding factor-β though their recruitment to the aforementioned en-
hancer element E8I [76]. Absence of E8I results in chromatin remodeling
and epigenetic silencing of the entire Cd8 cluster. Interestingly, E8I lies
within conserved non-coding regions in the human and murine CD8
cluster that undergo CREMα-instructed epigenetic remodeling in re-
sponse to TCR activation. Thus, it appears tempting to speculate that− (double negative) T cells in autoimmunity, Autoimmun Rev (2018),
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Fig. 2. Transcriptional regulation and epigenetic plasticity of the CD8 gene cluster. (A) Schematic map of the murine CD8 gene cluster comprising the Cd8A and Cd8B genes. Previously
reported DNAse I hypersensitive sites (HSS) I-IV [51] and CD8 expression regulating enhancer elements E8I–E8IV are displayed [53]. Eight recently reported conserved non-coding
sequences (CNS1–CNS8), deﬁned as regions of 200 bp with 70% homology between human and mouse genome [72], are depicted below and (at least partially) map to DNAse
hypersensitivity sites and enhancer elements. (B) Model of CREMα-mediated regulation of CD8 expression. CREMα controls transcriptional activity through trans-repression of the CD8B
promoter (CNS2) [72]. Furthermore, CREMα recruits to regulatory elements and co-recruits DNMT3a and histone methyltransferase G9a to the CD8 cluster (CNS 2,7,8). G9a mediates
methylation of histone H3 at H3K9 and H3K27. Resulting DNA and histone methylation results in stable epigenetic silencing of CD8A and CD8B [48]. Indeed, CREMα-instructed epigenetic
remodeling may reduce recruitment of additional transcriptional regulators, such as RUNX3 (required for CD8 co-receptor expression) to enhancer elements (e.g. E8I).
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play a central role in the transformation of CD8+ T cells into DN T cells
[75].
Another recent study linked the loss of CD8 expression in CD8+ T
cells from OT-I mice to IL-4-induced STAT6 activation in vitro and in
vivo [77]. In the same study, down-regulation of CD8 was linked to in-
creased DNA methylation of the Cd8a gene. During the generation of
DN T cells, STAT6 may orchestrate transcriptional repression of Cd8a
and DNA methylation either directly or through the induction of
GATA3 expression [78]. Interestingly, the presence of IFN-γ recovered
CD8 expression in a subset of DN T cells [77], suggesting that epigenetic
silencing of Cd8 in DN T cellsmay be reversible. Furthermore, epigenetic
plasticity of the Cd8 gene locus inmature CD8+ T cells strongly supports
the hypothesis that DN T cells can derive from CD8+ T cells [75].
Interestingly, studying the methylome of peripheral TCRαβ+ DN T
cells revealed subset-speciﬁc DNA methylation patterns when com-
pared to both CD4+ and CD8+ T cells. While regulatory elements of
the human CD8 cluster were hypermethylated as previously reported,
global DNA methylation was reduced in peripheral TCRαβ+ DN T cells
when compared to CD4+ and CD8+ T cells. In line with these observa-
tions, signiﬁcantly reduced expression of all three DNAmethyltransfer-
ases (DNMT1, DNMT3a, and DNMT3b) were seen in DN T cells. DistinctPlease cite this article as: Brandt D, Hedrich CM, TCRαβ+CD3+CD4−CD8
https://doi.org/10.1016/j.autrev.2018.02.001and highly consistent DNA methylation patterns in genes responsible
for cell interaction and adhesion, as well as (usually) Th1 (IFNG), Th2
(IL5), and Th17 (IL17F)-speciﬁc genes implicate a unique epigenetic ar-
chitecture in DN T cells that allows for a broad immune response [79].
4. Phenotypes and functional properties of DN T cells
Variable phenotypes of DN T cells have been described, indicating
that DN T cells, just as other T cell lineages, may be divided into subsets
[80]. Indeed, depending on activating stimuli or variable developmental
histories, DN T cells may exhibit distinct expression patterns of surface
co-receptors [80]. Nevertheless, DN T cells also exhibit consistent char-
acteristics observed in several studies. Human peripherally generated
DN T cells, for instance, express polyclonalαβ T cell receptor repertoires
[19]. Furthermore, DN T cells neither express natural killer (NK) cell
markers (CD56, CD16) nor classical markers of regulatory T cells, such
as FOXP3, CD25, or CTLA-4 [19,81]. Of note, reduced or even absent ex-
pression of the surface co-stimulatorymolecule CD28 appears to be rep-
resentative for the majority of peripheral blood DN T cells [82]. Of note,
CD28-deﬁcient T cells are generally considered antigen-experienced
and differentiated [83]. Indeed, DN T cells display characteristics of ter-
minally differentiated and “exhausted” T cells that underwent extensive− (double negative) T cells in autoimmunity, Autoimmun Rev (2018),
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(TRECs) [19] and the expression of the inhibitory molecule Pro-
grammed Cell Death Protein 1 (PD-1) [84,85]. In agreement with
these observations, DN T cells fail to proliferate in response to TCR com-
plex activation and display increased apoptosis as compared to CD4+ or
CD8+ T cells [32,69,85].
Taken together, aforementioned observations suggest effector phe-
notypes and a terminal differentiation status of DN T cells. Indeed, a sig-
niﬁcant proportion of freshly isolated or in vitro stimulated DN T cells,
display surface marker patterns (e.g. CCR7+ and CD45RA−) that are
characteristic for effector T cells [19,82,85]. Interestingly, in response
to TCR complex stimulation, the fraction of CD45RA− effector DN T
cells considerably increased in recent studies, implicating that activated
DN T cells favor differentiation into effector memory T cell phenotypes
[85,86]. The hypothesis that DN T cells may be terminally differentiated
is further supported by the observation that they fail to proliferate in re-
sponse to TCR complex stimulation and that the pool of DN T cells is
maintained or extended by de novo generation of DN T cells from
CD8+ T lymphocytes [69].
Several studies reported DN T cells to exhibit broad cytokine expres-
sion patterns. For instance, DN T cells spontaneously secrete the im-
mune regulatory cytokine IL-10 [19,69]. This observation is of
particular interest, since IL-10 is known to on the one hand exert anti-
inﬂammatory functions, e.g. through the suppression of T cell responses
[87], and on the other hand contributes to B cell activation, differentia-
tion, and antibody production [88,89]. Thus, IL-10 expression may be a
key mechanisms connecting effector with regulatory functions (see
below) of DN T cells. Effector functions of DN T cells are further sug-
gested by the expression of signature cytokines of effector T cell subsets.
We and others observed interferon (IFN-)γ expression in DN T cells in
response to TCR complex activation [19,85,69]. As IL-10, IFN-γ may
have dual function. While it contributes to tolerance-promoting effects
in transplantation, it is generally considered a Th1 speciﬁc pro-inﬂam-
matory cytokine that centrally contributes to systemic autoimmunity
in humans [90]. Both ex vivo isolated and in vitro generatedDNT express
an array of pro-inﬂammatory effector cytokines and chemokines, in-
cluding IL-1, IL-8, ICXCL3, and CXCL2 [69]. Also, DN T cells express the
pro-inﬂammatory effector cytokine IL-17 (IL-17A) that plays a central
role during physiological responses to bacteria and fungi, but also in tis-
sue and organ damage in autoimmune/inﬂammatory conditions [91].
However, IL-17 is not exclusively expressed by DN T cells in response
to infections and autoimmune diseases, but also in DN T cells derived
from healthy subjects [24,32,69,92]. Furthermore, activated DN T cells
produce the cytolytic protein perforin, but fail to express granzyme B,
another protein typical expressed in cytotoxic lymphocytes [19].
Effector T cells are not only characterized by increased expression of
lineage-deﬁning cytokines and chemokines (e.g. Th1 or Th17 cyto-
kines), but also by reduced expression of others. Double negative T
cells fail to express IL-2 when compared to CD4+ or CD8+ T-cells [19,
32, unpublished data from our group]. Indeed, reduced expression of
IL-2 is a key feature of effector T cells in SLE [93].
Rodriguez et al. recently identifying a self-reactive subset of DN T in
mice, characterized by the expression of PD-1 and the transcription fac-
tor Helios that had lost CD8 surface co-receptor expression in response
to activation in the periphery [94]. Of note, DN T cells were even found
during steady state in healthy animals. However, the absolute number
and percentage of PD-1+ DN T cells was increased inmice that accumu-
late self-reactive T cells as a consequence of defects in central (Aire−/−
mice) and peripheral tolerance (Faslpr mice) [7]. The cell surface recep-
tor PD-1 is involved in the maintenance of peripheral tolerance by the
suppression of activation induced T cell receptor signaling, thereby lim-
iting inﬂammatory responses [95]. More recently, PD-1 moved into the
focus of studies targeting peripheral tolerance and its disruption in au-
toimmune/inﬂammatory disease [96]. Indeed, PD-1 expressing DN T
cells represent the main source of pro-inﬂammatory cytokines within
the DN T cell compartment [7].Please cite this article as: Brandt D, Hedrich CM, TCRαβ+CD3+CD4−CD8
https://doi.org/10.1016/j.autrev.2018.02.001In addition to aforementioned effector functions, (at least) subsets of
DN T cells exert regulatory activity. Several murine systems and ex vivo
isolated human cells were applied to study regulatory functions of DN T
cells, reviewed in [80,87]. In response to peptide–HLA complex presen-
tation by antigen-presenting cells, human DN T cells inhibit antigen-
speciﬁc T cells [19]. In linewith data from studies in themurine system,
humanDN T cells exhibit cell-cell contact dependent suppressive effects
on CD4+ and CD8+ T cells in vitro [86]. Though the exact molecular
mechanisms remain elusive, this was independent of the Fas/FasL path-
way or perforin.
Taken together, gene expression patterns and functional properties
of DNT cells suggest thepresence of various regulatory and effector sub-
populations within the DN T cell compartment. However, a majority of
cellswithin theDNT cell compartment displays the phenotype of termi-
nally differentiated effector cells that are capable of pro-inﬂammatory
cytokine production.
5. Autoimmune disorders associated with DN T cell expansion
5.1. Autoimmune lymphoproliferative syndrome
Autoimmune lymphoproliferative syndrome (ALPS) is a rare disease
that is characterized by chronic nonmalignant lymphoproliferation,
hepatosplenomegaly, and autoimmune symptoms [97]. Chronic or re-
current cytopenia affecting multiple blood cell lines is one of the most
common ﬁndings, and due to autoimmune reactions (hemolytic ane-
mia, immune-mediated thrombocytopenia, and autoimmuneneutrope-
nia) or splenic sequestration [97]. Defective lymphocyte apoptosis is
caused by somatic or germline mutations in the FASL, or caspase
(CASP)10 gene, and results in the accumulation of lymphocytes [15]. Ac-
cumulation of DN T cells in the peripheral blood (N2.5% of CD3+ T cells)
and lymphoid tissues is a characteristic feature inmost of ALPS patients,
and therefore part of established diagnostic criteria [15]. Double nega-
tive T cells from ALPS patients share a unique CDR3 sequence with
CD8+ T cells across several TCRVβ families, suggesting that DN T cells
derive from CD8+ T cells [70]. Furthermore, data from studies in SLE
support this hypothesis. As cells from patients with SLE, also CD8+ T
cells fromMRL.lpr animals exhibit increased expression of the transcrip-
tion factor CREMα that contributes to the generation of effector DN T
cells from CD8+ T cells (see below under Section 4.2). This may indicate
a central contribution of CREMα to DN T cell generation in Fas-deﬁcient
animals (and potentially also ALPS patients). However, results require
to be interpreted with caution, since in contrast to MRL.lpr mice, Fas
and FasL expression and function are preserved in SLE patients [98],
and additional mechanisms may come into play. However, MRL.lpr an-
imals much rather resemble human ALPS (see above) than SLE.
The hypothesis that DN T cells may be involved in the onset of
autoimmunological symptoms in ALPS patients is supported by thephe-
notype of DN T cells that were isolated frompatientswith ALPS that dis-
tinctly differs from the phenotype of DN T cells fromhealthy individuals.
As DN T cells from Fas-deﬁcient MRL.lprmice, cells from ALPS patients
abnormally express the B cell antigen B220, an isoform of the CD45 an-
tigen (that used to be referred to as leukocyte common antigen; LCA)
[99]. Of note, the B cell marker B220 is alternatively expressed on acti-
vated T cells that undergo apoptosis [100].
Furthermore, DN T cells from ALPS patients co-express CD27 and
CD28 [101], a characteristic of naïve and central memory T cell subsets
that is usually absent in effector T cells [102]. However, also in ALPS pa-
tients, DN T cells are mature antigen experienced effector T lympho-
cytes and certainly not “naïve”. Of note, in contrast to DN T cells from
healthy individuals [69] or patients with other autoimmune/inﬂamma-
tory conditions [32,85], DN T cells from ALPS patients can and do prolif-
erate [70].
Another interesting observation that may be (at least partially)
caused or promoter by DN T cells is the presence of autoantibodies in
most ALPS patients that correlates with the number of DN T cells in− (double negative) T cells in autoimmunity, Autoimmun Rev (2018),
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tioned B cell promoting effects of the immune regulatory cytokine IL-
10, which is expressed at high levels by DN T cells from ALPS patients
[15,70].
5.2. Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a prototypical systemic auto-
immune disease and facilitated by inappropriate immune responses to
self-antigens, resulting in systemic inﬂammation and organ damage
[1]. Various T cell subsets, including effector CD4+ T helper cells, con-
tribute to the pathophysiology, tissue damage and disease expression
[1]. Over the past years, DN T cells moved into the focus of scientiﬁc
studies. Interest in DN T cells in SLE was ﬁrst generated through the ob-
servation that SLE patients exhibit increased numbers of DN T cells in
the peripheral blood [32,103] and that the number of DN T cells corre-
lates with disease activity [104]. Currently, we are still at the beginning
of understanding the exact contribution of DN T cells to the pathophys-
iology of SLE. However, ﬁrst evidence indicates a contribution of effector
DN T cells to tissue inﬂammation and organ damage [105]. Double neg-
ative T cells invade the kidneys of patientswith SLE-associated nephritis
[32], where they produce pro-inﬂammatory effector cytokines, activate
other T cells and induce immunoglobulin production [32,106]. Crispin et
al. demonstrated that DN T cells can derive from CD8+ T cells as a result
of TCR complex stimulation in vitro [32]. Based on these observations
others and we concluded that at least a majority of DN T cells derives
from activated (self-reactive) CD8+ T cells in SLE.
The pro-inﬂammatory effector cytokine IL-17A is an important con-
tributor to systemic inﬂammation and tissue damage in SLE [107]. Be-
sides CD4+ T helper cells, DN T cells represent a major source of IL-
17A in SLE patients [32]. The transcription factor cAMP responsive ele-
ment modulator (CREM)α is expressed at increased levels in T cells
from SLE patients (and MRL.lprmice) [108]. We recently demonstrated
that CREMα contributes to the down-regulation of CD8 expression and
the subsequent generation of DN T cells in cells from healthy controls
and (to a larger extent) SLE patients [72,75]. Because CREMα alsomedi-
ates increased IL-17A and reduced IL-2 expression in CD4+ effector T
cells [93], we hypothesized that CREMαmay be a central player during
the generation of effector DN T cells in SLE.
Several lines of evidence suggest that DN T furthermore contribute
to tissue damage through the promotion of anti-dsDNA antibody pro-
duction by B cells [103,104,109]. This may be caused by increased ex-
pression of activated mechanistic target of rapamycin complex 1
(mTORC1) in DN T cells [110]. Activation of mTOR triggers the produc-
tion of IL-4 by DN T cells, which correlates with B cell activation and the
production of dsDNA antibodies [104]. Indeed, treatment with the
mTOR inhibitor rapamycin reduces IL-4 production by DN T cells in pa-
tientswith SLE [104]. Of note,mTORpathway activation has been linked
with the transcription factor CREMα through the CREMα-dependent
regulation of the S6 kinase, a substrate of mTORC1 [111,112]. Thus,
the transcription factor CREMαmore and more appears to emerge as
a key element in the pathophysiology of SLE and potentially other auto-
immune/inﬂammatory conditions by its involvement in effector T cell
generation and resulting tissue damage [49].
5.3. Sjögren's syndrome
Sjögren's syndrome (SS) is a systemic autoimmune disease character-
ized by lymphocytic inﬁltration to exocrine glands (salivary) and lacrimal
glands that leads to chronic inﬂammation, tissue damage, and subse-
quently impaired secretory function [113]. Sjögren's syndrome may
occur either as primary disease, or as a secondary feature in other autoim-
mune diseases, such as SLE [114], rheumatoid arthritis, or systemic scle-
rosis [113]. Allunno et al. found DN T cells expanded in numbers in the
peripheral blood of SS patients. Furthermore, DN T cells inﬁltrate salivary
glands where they produce IL17A [92]. Indeed, several lines of evidencePlease cite this article as: Brandt D, Hedrich CM, TCRαβ+CD3+CD4−CD8
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in SS [115,116]. Surprisingly, DN T cells from patients with primary SS
displayed no response to corticosteroids in vitro, which is in line with in-
sufﬁcient therapeutic efﬁcacy of corticosteroids in SS patients [92].
In addition to T cell inﬁltration to exocrine glands, B cell hyperactiv-
ity and autoantibody production are typical features of SS. Aberrant B
cell maturation and activation is at least partiallymediated by increased
expression of the tumor necrosis factor (TNF) family member B cell ac-
tivating factor (BAFF). The cytokine BAFF is produced by various im-
mune cells, including activated lymphocytes and elevated in several
autoimmune conditions (including pSS and SLE) [117,118]. Interest-
ingly, in DN T cells increased BAFF expression and hypomethylation of
the BAFF encoding TNFSF13B gene, indicating transcriptional permis-
siveness, has been reported [79]. Furthermore, BAFF expression is in-
creased in the presence of IFN-γ [117], a cytokine which is also
expressed in DN T cells [69].
In summary, DN T cells may contribute to the pathogenesis of SS due
through IL-17 production and/or pathological B cell stimulation.
5.4. Psoriasis
Psoriasis is a systemic inﬂammatory condition that is characterized
by immune cell inﬁltration to the skin and excessive keratinocyte prolif-
eration [119]. IL-17-producing DN T cells have been linkedwith skin in-
ﬂammation in a mouse model of psoriasis [120]. Recently, we showed
that DNT cells inﬁltrate the epidermis in patientswith plaque-type pso-
riasis, suggesting a pathophysiological role of DNT cells in tissue inﬂam-
mation and damage [85]. Furthermore, DN T cells from psoriasis
patients exhibited reduced DNA methylation of an enhancer element
of the IFNG gene, suggesting increased accessibility to transcription fac-
tors [85]. Taken results from these studies together, DN T cells may con-
tribute to skin inﬂammation through the expression of the
inﬂammatory effector cytokines IFN-γ and IL-17.
Following the hypotheses that PD-1 expressing T cellsmay be crucial
players in autoimmune disease [96] and that PD-1+DN T cells represent
a self-reactive T cell subset [7], it is of special interest that surface PD-1
expression onDN T cells was generally increased in DN T cells from pso-
riasis patients, however, predominantly enriched in the epidermal
layers of psoriatic skin [85]. This highlights the assumptions that
plaque-type psoriasis may, in fact be a systemic autoimmune disease
[121,122] and that DN T cells may be centrally involvement in its path-
ophysiology [85].
6. Conclusion and perspective
Double negative T cells comprise a rare and heterogeneous T lym-
phocyte subset. While some evidence indicates regulatory functions of
DN T cells, recent studies report the involvement of self-reactive, pro-in-
ﬂammatory effector DN T cells in systemic inﬂammation and tissue
damage. Indeed, though rare in the peripheral blood of patients, DN T
cells inﬁltrate inﬂamed tissues and may contribute to organ damage.
Regardless of recent advances in understanding keymolecular elements
contributing to effector DN T cell generation, we are only beginning to
understand the complex mechanisms deﬁning individual phenotypes.
Thus, additional studies are warranted targeting the role of DN T cells
in health and autoimmune/inﬂammatory disease, and may bring us
closer to an application of DN T cells as disease biomarkers and/or ther-
apeutic targets.
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